(P142) Older Patients Derive Greater Benefit From Adjuvant and Neoadjuvant Radiotherapy in Diverse Solid Malignancies

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This is the largest analysis to date examining the effects of RT in a broad population of solid tumor patients. Although we were unable to control for chemotherapy use in this cohort, RT was associated with superior oncologic outcome compared with surgery alone among patients with multiple solid malignancies. This positive effect was most pronounced in older patients with breast and rectal cancer, suggesting age-dependent effects of RT.

Noah K. Yuen, MD, Arta Monjazeb, MD, PhD, Chin-Shang Li, PhD, Dariusz Borys, MD, Richard Bold, MD, Robert Canter, MD; University of California, Davis Medical Center

BACKGROUND: Radiation therapy (RT) is a standard component in the contemporary multimodality management of numerous solid malignancies. Increasing studies have shown that age-related immunologic changes may impact the bioactivity of RT. We hypothesized that outcomes of RT would be influenced by age across various solid cancers.

METHODS: Using Surveillance, Epidemiology, and End Results (SEER) data (1990–2011), we identified 959,731 adult patients (aged > 18 yr) with common nonmetastatic solid malignancies, including breast, lung, and rectal cancer, undergoing surgery ± RT. We compared patient demographics, tumor characteristics, and treatments by age. Multivariable analyses were used to examine the effect of these variables on overall survival (OS) and disease-specific survival (DSS). Hazard ratios were calculated based on multivariable Cox proportional hazards models and logistic regression analysis.

RESULTS: The study cohort consisted of 70.0% breast, 13.5% lung, 11.9% rectal, 3.4% sarcoma, and 1.2% esophageal cancer. Mean age at diagnosis was 61.1 ± 13.8 years, and 42% of patients were aged ≥ 65 years. A total of 43.2% received either adjuvant (39.0%) or neoadjuvant (4.2%) RT. With the exception of lung cancer (OS hazard ratio [HR] = 1.21; 1.19–1.23), RT was associated with improved survival in patients of all ages: breast (OS HR = 0.72; 0.71–0.73), rectal (OS HR = 0.81; 0.79–0.83), esophageal (OS HR = 0.83; 0.75–0.91), and sarcoma (OS HR = 0.63; 0.56–0.70). These positive effects were amplified in elderly patients (aged ≥ 65 yr), with breast (OS HR = 0.66; 0.65–0.66) and rectal cancers (OS HR = 0.74; 0.72–0.76) having the most benefit. On logistic regression, the HR for risk of death per year of age was lower in patients receiving RT vs those not receiving RT: breast (1.057–1.060 vs 1.072–1.074), rectal (1.043–1.048 vs 1.081–1.085), esophageal (1.006–1.023 vs 1.026–1.046), and lung cancer (1.039–1.047 vs 1.050–1.054).

CONCLUSIONS: This is the largest analysis to date examining the effects of RT in a broad population of solid tumor patients. Although we were unable to control for chemotherapy use in this cohort, RT was associated with superior oncologic outcome compared with surgery alone among patients with multiple solid malignancies. This positive effect was most pronounced in older patients with breast and rectal cancer, suggesting age-dependent effects of RT. Further investigation into the mechanism of these age-related effects is indicated.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content